Navigation Links
iCardiac Expands Sales and Marketing Team
Date:8/6/2009

Adds Industry Veteran with Over Two Decades of Cardiovascular Core Lab Experience

Rochester, NY (PRWEB) August 6, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety ECG services and automated QT analysis, announced that it has expanded its sales and marketing team by hiring Susan Boyle as Senior Director of Business Development. Ms. Boyle has over two decades of experience in operations and business development in the clinical research industry, specializing in centralized cardiovascular diagnostic services at a number of leading core laboratories.

"We are excited to welcome Susan to the iCardiac team," said Sasha Latypova, Executive Vice President. "Susan's deep client relationships and long history of successfully partnering with clinical pharmacology units will allow iCardiac to better serve its rapidly broadening set of customers and channel relationships."

"I am proud to join iCardiac at this exciting transformation point in the cardiac core laboratory industry," said Ms. Boyle. "iCardiac has driven a dramatic shift in the industry by establishing the company as both a leader in Highly Automated QT evaluation as well as advanced techniques for avoiding false positives and negatives in cardiac safety studies."

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for ECG/QT interval measurements, including Highly Automated QT, which has been validated by pharmaceutical companies and is now used in regulatory submissions as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

# # #

Read the full story at http://www.prweb.com/releases/icardiac/business/prweb2715644.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. iCardiac Selected for Multiple Cardiac Safety Studies
4. iCardiac Selected by Top 10 Pharmaceutical Company
5. iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies
6. ATS Medical Expands Open Pivot Heart Valve Offerings
7. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
8. BioLife Solutions Expands Scientific Advisory Board
9. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
10. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
11. Pharsight Expands Strategic Consulting Services Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell ... RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture processes, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):